1. Executive Validation and Strategic Context

The Centers for Medicare & Medicaid Services (CMS) finalized the Ambulatory Specialty Model (ASM) in the CY 2026 Medicare Physician Fee Schedule (PFS) final rule on October 31, 2025 (90 FR 32565). ASM represents a watershed moment in federal payment reform: it is CMMI’s first mandatory alternative payment model (APM) targeting specialists treating chronic conditions in ambulatory settings. Unlike every prior CMMI specialty-adjacent initiative, ASM is not voluntary, carries no opt-out pathway, and imposes two-sided financial risk directly on individual clinicians identified by TIN/NPI.

The model’s strategic significance extends far beyond its immediate scope. CMS has signaled its intent to have 100 percent of traditional Medicare beneficiaries in accountable care models by 2030. To date, that ambition has been driven almost exclusively through primary care and ACO constructs—MSSP, ACO REACH, Primary Care First, Making Care Primary. ASM and its companion model TEAM (Transforming Episode Accountability Model, targeting acute care hospitals) together represent the expansion of mandatory value-based payment into the two remaining domains: specialty care and facility-based episodes.

The selection of heart failure and low back pain as the initial conditions is deliberate. Heart failure represents approximately $10–13 billion in annual Medicare Parts A and B spending, with persistent variation in guideline-directed medical therapy (GDMT) adherence, high hospitalization rates, and inconsistent care-transition patterns. Low back pain accounts for $6–8 billion, with documented overutilization of imaging, injections, and surgical interventions. Together, these two conditions represent roughly 6% of total annual traditional Medicare spending—a massive economic target for a model covering approximately one-quarter of the nation’s metropolitan statistical areas.

Strategic Recommendation: ASM is not a pilot. It is the prototype for how CMS intends to bring all specialty care under value-based accountability. Organizations that treat this as a compliance exercise rather than a strategic transformation will be structurally disadvantaged when the model expands to additional conditions and geographies in subsequent rulemaking cycles.

2. Model Architecture and Temporal Dynamics

2.1 Timeline and Performance Periods

The ASM operates on a five-year performance window with a two-year payment lag—a structure that creates both planning certainty and delayed financial consequence.

Performance Year	Payment Year	Risk Level	Key Date
2027	2029	±9%	Model launches Jan 1, 2027
2028	2030	±9%	Steady state
2029	2031	±10%	Risk level increases
2030	2032	±11%	Risk level increases
2031	2033	±12%	Final performance year; max risk

The two-year lag between performance and payment is critical for financial planning. A cardiologist who performs poorly in 2027 will not experience the revenue impact until 2029. Conversely, strong performance in 2027 generates no financial reward until 2029. This delay creates a behavioral challenge: the feedback loop is so slow that organizations may not recognize underperformance until substantial financial exposure has already accumulated across two performance years.

Rulemaking Authority: ASM was proposed in the CY 2026 PFS proposed rule (July 14, 2025, 90 FR 32565) and finalized in the CY 2026 PFS final rule (published November 5, 2025). Because it was codified through notice-and-comment rulemaking rather than CMMI’s standard Section 1115A waiver authority, ASM has a different legal standing than most CMMI models—it is embedded in the PFS regulatory framework.

2.2 Participant Identification Timeline

CMS has published the following participant notification schedule:

Milestone	Timing	Data Basis
Preliminary participant list	Early 2026 (est. Q1)	2024 claims data
Final participant list	July 2026	2025 claims data
Performance year begins	January 1, 2027	N/A
Annual re-assessment	Each subsequent year	Prior year claims

Implications: Organizations have approximately 6 months between the final participant list (July 2026) and the January 2027 start date. This is an extremely compressed preparation window for a model that requires executed Collaborative Care Arrangements (CCAs) with primary care practices, CEHRT implementation, quality measure reporting infrastructure, and episode cost management capabilities. Organizations that wait for the final list to begin preparation will be structurally behind.

2.3 The Permanence Trap

Once a physician qualifies for ASM in any performance year, the physician is treated as an ASM participant for the duration of the model for purposes of cohort benchmarking, even if they fall below the 20-episode volume threshold in a later year. This “once-in, always-in” design prevents gaming through patient panel manipulation. A cardiologist cannot strategically reduce their Medicare HF caseload below 20 to escape the model—they remain in the cohort for benchmarking purposes. However, they may not receive a payment adjustment if they fail to meet data submission requirements for a particular year.

Strategic Recommendation: Physicians considering retirement, practice relocation, or subspecialty transitions within the 2027–2031 window should model the financial implications of ASM participation carefully. The ‘once-in, always-in’ rule means that a physician who qualifies in 2027 and reduces their Medicare panel in 2029 is still benchmarked against active ASM participants—potentially creating unfavorable comparisons.